ISRCTN58831878 https://doi.org/10.1186/ISRCTN58831878

A randomised trial of high dose therapy and autologous bone marrow transplantation versus continuing conventional combination chemotherapy for adults with lymphoblastic lymphoma

Submission date 01/07/2001	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 01/07/2001	**Overall study status** Completed	
Last Edited 28/11/2019	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

Protocol serial number
LY01

Study information

Scientific Title
A randomised trial of high dose therapy and autologous bone marrow transplantation versus continuing conventional combination chemotherapy for adults with lymphoblastic lymphoma

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Primary study design
Interventional

Study design
Randomised controlled trial

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Lymphoma (non-Hodgkin's) cancer

Interventions
All patients receive induction therapy and conventional chemotherapy regimens.
Patients achieving complete remission or partial remission are randomised to either:
1. Regimen A: Continue therapy on conventional regimen. The recommended conventional regimen is modified LSA2L2.
2. Regimen B: High dose therapy and ABMT.

Intervention Type
Drug

Phase
Not Applicable

Primary outcome(s)
Not provided at time of registration

Key secondary outcome(s)
Not provided at time of registration

Completion date
30/04/1997

Eligibility

Key inclusion criteria

1. Histologically documented lymphoblastic lymphoma
2. No prior chemotherapy or radiotherapy, except chemotherapy given for immediate relief of symptoms at presentation
3. Age 15 or over
4. All stages
5. No circulating blasts
6. Normal values for renal and hepatic function, unless directly attributable to lymphoma
7. Normal cardiac function
8. No evidence of Human Immunodeficiency Virus (HIV) infection

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Sex
All

Total final enrolment
119

Key exclusion criteria
Patients will be excluded if they have HLA-identical siblings who are undergoing allogenic bone marrow transplantation. These patients should be registered with the trials office but will not be randomised.

Date of first enrolment
01/01/1992

Date of final enrolment
30/04/1997

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Cancer Research UK (CRUK) (UK)

ROR
https://ror.org/054225q67

Funder(s)

Funder type
Charity

Funder Name
Cancer Research UK

Alternative Name(s)
CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type
Private sector organisation

Funding Body Subtype
Other non-profit organizations

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/06/2001	28/11/2019	Yes	No